Population Pharmacokinetics of Piperacillin and Tazobactam in Critically Ill Patients Receiving Extracorporeal Membrane Oxygenation: an ASAP ECMO Study

Our study aimed to describe the population pharmacokinetics (PK) of piperacillin and tazobactam in patients on extracorporeal membrane oxygenation (ECMO), with and without renal replacement therapy (RRT). We also aimed to use dosing simulations to identify the optimal dosing strategy for these patie...

Full description

Saved in:
Bibliographic Details
Published in:Antimicrobial agents and chemotherapy 2021-10, Vol.65 (11), p.e0143821
Main Authors: Cheng, Vesa, Abdul-Aziz, Mohd H, Burrows, Fay, Buscher, Hergen, Cho, Young-Jae, Corley, Amanda, Diehl, Arne, Gilder, Eileen, Jakob, Stephan M, Kim, Hyung-Sook, Levkovich, Bianca J, Lim, Sung Yoon, McGuinness, Shay, Parke, Rachael, Pellegrino, Vincent, Que, Yok-Ai, Reynolds, Claire, Rudham, Sam, Wallis, Steven C, Welch, Susan A, Zacharias, David, Fraser, John F, Shekar, Kiran, Roberts, Jason A
Format: Article
Language:English
Subjects:
Anti-Bacterial Agents
Antimicrobial Chemotherapy
Clinical Therapeutics
Critical Illness
Extracorporeal Membrane Oxygenation
Humans
Piperacillin
Tazobactam
Citations: Items that this one cites
Items that cite this one
Online Access:Get full text
Tags: Add Tag
No Tags, Be the first to tag this record!
Description
Summary:Our study aimed to describe the population pharmacokinetics (PK) of piperacillin and tazobactam in patients on extracorporeal membrane oxygenation (ECMO), with and without renal replacement therapy (RRT). We also aimed to use dosing simulations to identify the optimal dosing strategy for these patient groups. Serial piperacillin and tazobactam plasma concentrations were measured with data analyzed using a population PK approach that included staged testing of patient and treatment covariates. Dosing simulations were conducted to identify the optimal dosing strategy that achieved piperacillin target exposures of 50% and 100% fraction of time free drug concentration is above MIC (% ) and toxic exposures of greater than 360 mg/liter. The tazobactam target of percentage of time free concentrations of >2 mg/liter was also assessed. Twenty-seven patients were enrolled, of which 14 patients were receiving concurrent RRT. Piperacillin and tazobactam were both adequately described by two-compartment models, with body mass index, creatinine clearance, and RRT as significant predictors of PK. There were no substantial differences between observed PK parameters and published parameters from non-ECMO patients. Based on dosing simulations, a 4.5-g every 6 hours regimen administered over 4 hours achieves high probabilities of efficacy at a piperacillin MIC of 16 mg/liter while exposing patients to a
ISSN:0066-4804
1098-6596
DOI:10.1128/AAC.01438-21